Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301]-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301]

Published:2017-09-14 Issue:5 Volume:35 Page:e12278
ISSN:1755-5914
Container-title:Cardiovascular Therapeutics
language:en
Short-container-title:Cardiovasc Ther

Author:

Wang Ellen Q.¹,Plotka Anna²,Salageanu Joanne³,Sattler Catherine⁴,Yunis Carla⁵

Affiliation:

1. Clinical Pharmacology; Global Product Development; Pfizer Inc; New York NY USA

2. Global Biometrics and Data Management; Global Product Development; Pfizer Inc, Collegeville PA USA

3. Clinical Pharmacology; Global Product Development; Pfizer Inc; Groton CT USA

4. Clinical Sciences and Operations; Global Product Development; Pfizer Inc; Groton CT USA

5. Global Product Development CVMET Therapeutics; Pfizer Inc; New York NY USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1755-5922.12278/fullpdf

Reference34 articles.

1. PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9;Tavori;Curr Opin Endocrinol Diabetes Obes,2015

2. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia;Verbeek;Eur J Pharmacol,2015

3. PCSK9: a key modulator of cardiovascular health;Seidah;Circ Res,2014

4. Lipid lowering with PCSK9 inhibitors;Dadu;Nat Rev Cardiol,2014

5. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events;Sabatine;N Engl J Med,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives;Current Atherosclerosis Reports;2024-07-15

2. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22

3. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives;Drug Metabolism and Disposition;2022-02-11

4. Clinical development of automated subcutaneous injection devices—established pathways and novel concepts;Formulation and Device Lifecycle Management of Biotherapeutics;2022

5. Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins;Journal of Controlled Release;2021-08